Top Markets
Coin of the day
Health-Chem Corporation Health-Chem Corporation

Health-Chem Corporation

HCLC
Peringkat dalam Saham #40843
Health-Chem Corporation, operating through its subsidiary, Transderm... Health-Chem Corporation, operating through its subsidiary, Transderm Laboratories Corporation, specializes in the research, development, manufacturing, and commercialization of transdermal drug delivery systems throughout the United States. Among its key products are transdermal nitroglycerin patches, formulated to provide relief for vascular and cardiovascular symptoms linked to angina pectoris (commonly known as chest pain) via skin absorption. The company additionally offers contract research and development services to third-party clients. Health-Chem Corporation employs a multifaceted sales strategy, directly engaging with wholesalers, distributors, prominent retail pharmacy chains, mail-order pharmacies, and group purchasing organizations. Its products also reach the market indirectly through independent pharmacies, managed care organizations, hospitals, nursing homes, and pharmacy benefit management firms. Founded in 1970, the company's headquarters are situated in Emigsville, Pennsylvania.
Harga Saham
$0.0001
Terakhir disinkronkan: 2025-01-02
Kapitalisasi Pasar
$73.99K
Perubahan (1 hari)
0.00%
Perubahan (1 tahun)
0.00%
Negara
US
Perdagangan Health-Chem Corporation (HCLC)

Kategori

Laba untuk Health-Chem Corporation (HCLC)
Laba pada 2026 TTM: 0
Menurut laporan keuangan terbaru dari Health-Chem Corporation, laba saat ini perusahaan adalah 0. Pada tahun 2026, perusahaan memperoleh laba sebesar 0, sama dengan laba tahun 2026 sebesar 0. Laba yang ditampilkan di halaman ini adalah laba sebelum bunga dan pajak, atau disebut juga EBIT.
Riwayat laba untuk Health-Chem Corporation dari 2026 hingga 2026
Laba pada akhir setiap tahun
Tahun Laba Mengubah
Tidak cukup data untuk tanggal yang disediakan.
Laba untuk perusahaan serupa atau pesaing
Perusahaan Laba Perbedaan Laba Negara
$7.61B -
US
$4.76B -
US
- -
CN
$-252.70M -
US
$1.42B -
US